Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate |
2019-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2022-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2022512866-A |
titleOfInvention |
Anti-LAG3 antibody dosing regimen for treating cancer and combination therapy with anti-PD-1 antibody |
abstract |
The present invention relates to a dosing regimen of anti-LAG3 antibodies useful for the treatment of cancer. In particular, the invention is in a combination therapy comprising administering an antibody for programmed death 1 protein (PD-1) or a programmed death ligand 1 (PD-L1) and an antibody for lymphocyte activation gene 3 (LAG3). Regarding the medication regimen. The present invention is also a method for treating cancer in a patient, which comprises administering the patient with an anti-LAG3 antibody and an anti-PD-1 antibody, wherein the tumor tissue section of the patient is PD-L1 expression positive. , And the method may be positive for LAG3 expression. [Selection diagram] FIG. 12 |
priorityDate |
2018-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |